The gamma passing rates and critical indicators of the target area in brain cancer cases (mean ± SD).
| . | Criteria . | TB . | TBR . | CT+TB . | CT+TBR . |
|---|---|---|---|---|---|
| Body (%) | 3 mm/3% | 87.1 ± 5.9 | 98.6 ± 1.6 | 98.6 ± 1.6 | 99.5 ± 0.5 |
| 3 mm/2% | 86.6 ± 6.1 | 98.4 ± 1.7 | 98.4 ± 1.7 | 99.4 ± 0.6 | |
| 2 mm/2% | 78.3 ± 9.2 | 96.0 ± 3.4 | 96.7 ± 2.9 | 98.3 ± 1.3 | |
| PTV (%) | 3 mm/3% | 53.7 ± 12.4 | 94.6 ± 7.1 | 99.8 ± 0.3 | 99.6 ± 0.7 |
| 3 mm/2% | 52.9 ± 12.4 | 94.1 ± 7.4 | 99.7 ± 0.5 | 99.3 ± 1.1 | |
| 2 mm/2% | 37.0 ± 9.5 | 85.0 ± 13.4 | 98.3 ± 3.0 | 98.1 ± 2.1 | |
| GTV (%) | 3 mm/3% | 39.1 ± 13.3 | 93.2 ± 8.5 | 99.8 ± 0.4 | 99.4 ± 1.0 |
| 3 mm/2% | 38.3 ± 13.3 | 92.5 ± 8.9 | 99.6 ± 0.7 | 99.0 ± 1.5 | |
| 2 mm/2% | 20.1 ± 7.8 | 80.9 ± 16.0 | 97.8 ± 3.7 | 97.3 ± 3.2 | |
| (nCI, HI, and GI) | |||||
| Clinical planning | TBR | CT+TB | CT+TBR | ||
| nCI | 1.02 ± 0.01 | 1.01 ± 0.01 | 1.02 ± 0.01 | 1.02 ± 0.01 | |
| HI | 1.31 ± 0.04 | 1.36 ± 0.05 | 1.34 ± 0.05 | 1.31 ± 0.05 | |
| GI | 1.02 ± 0.01 | 1.01 ± 0.01 | 1.02 ± 0.01 | 1.02 ± 0.01 | |
| . | Criteria . | TB . | TBR . | CT+TB . | CT+TBR . |
|---|---|---|---|---|---|
| Body (%) | 3 mm/3% | 87.1 ± 5.9 | 98.6 ± 1.6 | 98.6 ± 1.6 | 99.5 ± 0.5 |
| 3 mm/2% | 86.6 ± 6.1 | 98.4 ± 1.7 | 98.4 ± 1.7 | 99.4 ± 0.6 | |
| 2 mm/2% | 78.3 ± 9.2 | 96.0 ± 3.4 | 96.7 ± 2.9 | 98.3 ± 1.3 | |
| PTV (%) | 3 mm/3% | 53.7 ± 12.4 | 94.6 ± 7.1 | 99.8 ± 0.3 | 99.6 ± 0.7 |
| 3 mm/2% | 52.9 ± 12.4 | 94.1 ± 7.4 | 99.7 ± 0.5 | 99.3 ± 1.1 | |
| 2 mm/2% | 37.0 ± 9.5 | 85.0 ± 13.4 | 98.3 ± 3.0 | 98.1 ± 2.1 | |
| GTV (%) | 3 mm/3% | 39.1 ± 13.3 | 93.2 ± 8.5 | 99.8 ± 0.4 | 99.4 ± 1.0 |
| 3 mm/2% | 38.3 ± 13.3 | 92.5 ± 8.9 | 99.6 ± 0.7 | 99.0 ± 1.5 | |
| 2 mm/2% | 20.1 ± 7.8 | 80.9 ± 16.0 | 97.8 ± 3.7 | 97.3 ± 3.2 | |
| (nCI, HI, and GI) | |||||
| Clinical planning | TBR | CT+TB | CT+TBR | ||
| nCI | 1.02 ± 0.01 | 1.01 ± 0.01 | 1.02 ± 0.01 | 1.02 ± 0.01 | |
| HI | 1.31 ± 0.04 | 1.36 ± 0.05 | 1.34 ± 0.05 | 1.31 ± 0.05 | |
| GI | 1.02 ± 0.01 | 1.01 ± 0.01 | 1.02 ± 0.01 | 1.02 ± 0.01 | |
For an mm/b% gamma passing rate, voxel “pass” if at least one voxel in the predicted dose distribution is within an mm range of that voxel and the dose received is within the ±b% range of that voxel dose value in the clinical plan. The passing rate represents the percentage of the passing voxels. The larger the value is, the better the predicted result is. The target area’s nCI, HI, and GI are critical indicators to evaluate plan quality in clinical practice. The closer the nCI is to 1, the better the result is.
Abbreviations: GI = gradient index; GTV = gross tumour volume; HI = homogeneity index; nCI = new conformity index; PTV = planning target volume.
The gamma passing rates and critical indicators of the target area in brain cancer cases (mean ± SD).
| . | Criteria . | TB . | TBR . | CT+TB . | CT+TBR . |
|---|---|---|---|---|---|
| Body (%) | 3 mm/3% | 87.1 ± 5.9 | 98.6 ± 1.6 | 98.6 ± 1.6 | 99.5 ± 0.5 |
| 3 mm/2% | 86.6 ± 6.1 | 98.4 ± 1.7 | 98.4 ± 1.7 | 99.4 ± 0.6 | |
| 2 mm/2% | 78.3 ± 9.2 | 96.0 ± 3.4 | 96.7 ± 2.9 | 98.3 ± 1.3 | |
| PTV (%) | 3 mm/3% | 53.7 ± 12.4 | 94.6 ± 7.1 | 99.8 ± 0.3 | 99.6 ± 0.7 |
| 3 mm/2% | 52.9 ± 12.4 | 94.1 ± 7.4 | 99.7 ± 0.5 | 99.3 ± 1.1 | |
| 2 mm/2% | 37.0 ± 9.5 | 85.0 ± 13.4 | 98.3 ± 3.0 | 98.1 ± 2.1 | |
| GTV (%) | 3 mm/3% | 39.1 ± 13.3 | 93.2 ± 8.5 | 99.8 ± 0.4 | 99.4 ± 1.0 |
| 3 mm/2% | 38.3 ± 13.3 | 92.5 ± 8.9 | 99.6 ± 0.7 | 99.0 ± 1.5 | |
| 2 mm/2% | 20.1 ± 7.8 | 80.9 ± 16.0 | 97.8 ± 3.7 | 97.3 ± 3.2 | |
| (nCI, HI, and GI) | |||||
| Clinical planning | TBR | CT+TB | CT+TBR | ||
| nCI | 1.02 ± 0.01 | 1.01 ± 0.01 | 1.02 ± 0.01 | 1.02 ± 0.01 | |
| HI | 1.31 ± 0.04 | 1.36 ± 0.05 | 1.34 ± 0.05 | 1.31 ± 0.05 | |
| GI | 1.02 ± 0.01 | 1.01 ± 0.01 | 1.02 ± 0.01 | 1.02 ± 0.01 | |
| . | Criteria . | TB . | TBR . | CT+TB . | CT+TBR . |
|---|---|---|---|---|---|
| Body (%) | 3 mm/3% | 87.1 ± 5.9 | 98.6 ± 1.6 | 98.6 ± 1.6 | 99.5 ± 0.5 |
| 3 mm/2% | 86.6 ± 6.1 | 98.4 ± 1.7 | 98.4 ± 1.7 | 99.4 ± 0.6 | |
| 2 mm/2% | 78.3 ± 9.2 | 96.0 ± 3.4 | 96.7 ± 2.9 | 98.3 ± 1.3 | |
| PTV (%) | 3 mm/3% | 53.7 ± 12.4 | 94.6 ± 7.1 | 99.8 ± 0.3 | 99.6 ± 0.7 |
| 3 mm/2% | 52.9 ± 12.4 | 94.1 ± 7.4 | 99.7 ± 0.5 | 99.3 ± 1.1 | |
| 2 mm/2% | 37.0 ± 9.5 | 85.0 ± 13.4 | 98.3 ± 3.0 | 98.1 ± 2.1 | |
| GTV (%) | 3 mm/3% | 39.1 ± 13.3 | 93.2 ± 8.5 | 99.8 ± 0.4 | 99.4 ± 1.0 |
| 3 mm/2% | 38.3 ± 13.3 | 92.5 ± 8.9 | 99.6 ± 0.7 | 99.0 ± 1.5 | |
| 2 mm/2% | 20.1 ± 7.8 | 80.9 ± 16.0 | 97.8 ± 3.7 | 97.3 ± 3.2 | |
| (nCI, HI, and GI) | |||||
| Clinical planning | TBR | CT+TB | CT+TBR | ||
| nCI | 1.02 ± 0.01 | 1.01 ± 0.01 | 1.02 ± 0.01 | 1.02 ± 0.01 | |
| HI | 1.31 ± 0.04 | 1.36 ± 0.05 | 1.34 ± 0.05 | 1.31 ± 0.05 | |
| GI | 1.02 ± 0.01 | 1.01 ± 0.01 | 1.02 ± 0.01 | 1.02 ± 0.01 | |
For an mm/b% gamma passing rate, voxel “pass” if at least one voxel in the predicted dose distribution is within an mm range of that voxel and the dose received is within the ±b% range of that voxel dose value in the clinical plan. The passing rate represents the percentage of the passing voxels. The larger the value is, the better the predicted result is. The target area’s nCI, HI, and GI are critical indicators to evaluate plan quality in clinical practice. The closer the nCI is to 1, the better the result is.
Abbreviations: GI = gradient index; GTV = gross tumour volume; HI = homogeneity index; nCI = new conformity index; PTV = planning target volume.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
